Aptose to Present at 2022 RBC Capital Markets Global Healthcare Conference
Aptose Biosciences announced that Dr. William G. Rice will participate in the 2022 RBC Capital Markets Global Healthcare Conference on May 17, 2022, from 3:30 to 4:00 p.m. ET. The event features a fireside chat moderated by Gregory J. Renza, M.D. The management team will also host 1x1 meetings during the conference. Aptose is a clinical-stage biotechnology company focused on developing targeted therapies for hematologic malignancies. Their pipeline includes two investigational products for treating acute myeloid leukemia and B-cell malignancies.
- None.
- None.
SAN DIEGO and TORONTO, May 03, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that Dr. William G. Rice, Chairman, President and CEO of Aptose, will participate in the RBC Capital Markets Global Healthcare Conference:
2022 RBC Capital Markets Global Healthcare Conference
| Date: | May 17, 2022 | |
| Time: | 3:30 – 4:00 p.m. ET | |
| Format: | Fireside Chat moderated by Gregory J. Renza, M.D., Equity Research – Biotechnology | |
| Webcast: | Link | |
The Aptose management team also will be hosting 1x1 meetings during the events.
About Aptose
Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage investigational products under development for hematologic malignancies: HM43239, an oral, myeloid kinome inhibitor in an international Phase 1/2 trial in patients with relapsed or refractory acute myeloid leukemia (AML); and luxeptinib, an oral, dual lymphoid and myeloid kinome inhibitor in a Phase 1 a/b trial in patients with relapsed or refractory B-cell malignancies who have failed or are intolerant to standard therapies, and in a separate Phase 1 a/b trial in patients with relapsed or refractory AML or high-risk myelodysplastic syndrome (MDS). For more information, please visit www.aptose.com.
For further information, please contact:
| Aptose Biosciences Inc. Susan Pietropaolo Investor Relations 201-923-2049 spietropaolo@aptose.com | LifeSci Advisors, LLC Dan Ferry, Managing Director 617-535-7746 Daniel@LifeSciAdvisors.com |
FAQ
What is Aptose participating in on May 17, 2022?
Who will represent Aptose at the RBC Conference?
What are the timing details for Aptose's session at the RBC Conference?
What is the format of Aptose's participation in the RBC Conference?
What products is Aptose developing for hematologic malignancies?
Where can I find the webcast link for Aptose's conference session?
